Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NicVAX Immunogenicity and Safety in Smokers
NCT00598325Phase 2Completed
- Sponsor
- Nabi Biopharmaceuticals
- Start
- Jan 2008
- Primary completion
- Oct 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of NicVAX in nicotine dependence (2 arms), sponsored by Nabi Biopharmaceuticals. Primary endpoint: Anti-nicotine antibody concentration at Week 20. Started Jan 2008; status: completed.
02
Drugs
NicVAX
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00598325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00598325.